Trial Profile
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms CaboGIST
- 01 Jun 2022 Results published in the Acta Oncologica
- 14 Jul 2021 Status changed from active, no longer recruiting to completed.
- 21 Mar 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record. (Global end date: 2021-02-23)